At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CNTA Centessa Pharmaceuticals plc
Market Closed 04-24 16:00:00 EDT
39.47
+0.04
+0.10%
盘后39.47
+0.000.00%
16:10 EDT
High39.50Low39.36Vol2.02M
Open39.49D1 Closing39.43Amplitude0.36%
Mkt Cap6.10BTradable Cap3.53BTotal Shares154.57M
T/O79.58MT/O Rate2.26%Tradable Shares89.33M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Centessa Pharmaceuticals (CNTA) and Perspective Therapeutics (CATX)
TIPRANKS  ·  04-20
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Centessa Pharmaceuticals (CNTA) and Perspective Therapeutics (CATX)
Wells Fargo Downgrades Centessa Pharmaceuticals ADR to Equal Weight From Overweight, Adjusts Price Target to $42 From $35
MT Newswires Live  ·  04-20
Wells Fargo Downgrades Centessa Pharmaceuticals ADR to Equal Weight From Overweight, Adjusts Price Target to $42 From $35
Centessa downgraded to Equal Weight from Overweight at Wells Fargo
TIPRANKS  ·  04-20
Centessa downgraded to Equal Weight from Overweight at Wells Fargo
Centessa Pharmaceuticals Plc : Truist Securities Cuts to Hold From Buy
THOMSON REUTERS  ·  04-13
Centessa Pharmaceuticals Plc : Truist Securities Cuts to Hold From Buy
Centessa downgraded to Hold from Buy at Truist
TIPRANKS  ·  04-13
Centessa downgraded to Hold from Buy at Truist
The Trader: Biotechs Are a Healthy Growth Bet. Thank M&A and New Drugs. -- Barron's
Dow Jones  ·  04-04
The Trader: Biotechs Are a Healthy Growth Bet. Thank M&A and New Drugs. -- Barron's
Centessa Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners
Dow Jones  ·  04-02
Centessa Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners
Centessa Pharmaceuticals PLC reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  04-02
Centessa Pharmaceuticals PLC reports results for the quarter ended December 31 - Earnings Summary
Centessa downgraded to Neutral from Buy at Guggenheim
TIPRANKS  ·  04-02
Centessa downgraded to Neutral from Buy at Guggenheim
Centessa Pharmaceuticals Agrees To Eli Lilly Acquisition At 40% Premium
Benzinga_recent_news  ·  04-01
Centessa Pharmaceuticals Agrees To Eli Lilly Acquisition At 40% Premium
Eli Lilly Diversifies from Weight-Loss Drugs to Sleep Disorders with Up to $7.8 Billion Centessa Acquisition
Deep News  ·  04-01
Eli Lilly Diversifies from Weight-Loss Drugs to Sleep Disorders with Up to $7.8 Billion Centessa Acquisition
BUZZ-Street View: Lilly's $7.8 billion Centessa buyout validates sleep‑drug market
Reuters  ·  04-01
BUZZ-Street View: Lilly's $7.8 billion Centessa buyout validates sleep‑drug market
Centessa downgraded to Market Perform from Outperform at LifeSci Capital
TIPRANKS  ·  04-01
Centessa downgraded to Market Perform from Outperform at LifeSci Capital
B. Riley Downgrades Centessa Pharmaceuticals to Neutral From Buy, Lifts Price Target to $45 From $42
MT Newswires Live  ·  04-01
B. Riley Downgrades Centessa Pharmaceuticals to Neutral From Buy, Lifts Price Target to $45 From $42
Centessa Pharmaceuticals Plc : Leerink Partners Cuts to Market Perform From Outperform; Raises Target Price to $40 From $36
THOMSON REUTERS  ·  04-01
Centessa Pharmaceuticals Plc : Leerink Partners Cuts to Market Perform From Outperform; Raises Target Price to $40 From $36
Centessa Pharmaceuticals Plc : Stephens Cuts to Equal Weight From Overweight; Raises Target Price to $47 From $35
THOMSON REUTERS  ·  04-01
Centessa Pharmaceuticals Plc : Stephens Cuts to Equal Weight From Overweight; Raises Target Price to $47 From $35
Nxera partner Centessa agrees to be acquired by Lilly
Reuters  ·  04-01
Nxera partner Centessa agrees to be acquired by Lilly
Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ
Dow Jones  ·  04-01
Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ
Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com
Dow Jones  ·  04-01
Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com
Centessa Pharmaceuticals: IF Deal With Eli Lilly Terminated Under Certain Circumstances, Co to Pay Eli Lilly a Termination Fee of About $63 Mln
THOMSON REUTERS  ·  04-01
Centessa Pharmaceuticals: IF Deal With Eli Lilly Terminated Under Certain Circumstances, Co to Pay Eli Lilly a Termination Fee of About $63 Mln
No data available

Introduction

Company Name.
Centessa Pharmaceuticals plc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Issue price:
--